Market Overview - The chemical pharmaceutical sector increased by 0.76% on February 4, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Gainers in Chemical Pharmaceutical Sector - Guangshantang (300436) closed at 116.01, up 7.50% with a trading volume of 144,300 shares and a transaction value of 16.55 billion [1] - Xinlitai (002294) closed at 48.15, up 4.27% with a trading volume of 118,000 shares and a transaction value of 564 million [1] - Zehao Pharmaceutical (688266) closed at 90.30, up 4.19% with a trading volume of 31,500 shares and a transaction value of 280 million [1] - Other notable gainers include Puluo Pharmaceutical (000739) and Shutaishen (300204), with increases of 4.17% and 4.14% respectively [1] Top Losers in Chemical Pharmaceutical Sector - Xinnoway (300765) closed at 35.80, down 3.79% with a trading volume of 126,300 shares [2] - Tonghua Jinma (000766) closed at 23.57, down 3.72% with a trading volume of 352,100 shares and a transaction value of 814 million [2] - Changshan Pharmaceutical (300255) closed at 48.63, down 3.09% with a trading volume of 246,200 shares and a transaction value of 1.186 billion [2] Capital Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 39.83 million from institutional investors, while retail investors experienced a net outflow of 190 million [2][3] - Notable net inflows from institutional investors include ST Renfu (600079) with 123 million and Guangshantang (300436) with 110 million [3] - Retail investors showed significant outflows from ST Renfu (600079) and Guangshantang (300436), with outflows of 71.99 million and 86.96 million respectively [3]

本次GST-HG141完成III期临床试验全部受试者入组后，尚需按照已制定临床方案和要求继续推进临床 试验，并经国家药品审评部门注册审批通过后方可上市。 智通财经APP讯，广生堂(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在 研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入 组578例。 ...

奈瑞可韦 GST-HG141 是新型乙肝核心蛋白/核衣壳调节剂，属于全新机制的 在研抗乙肝病毒的一类创新药。迄今为止，全球范围内尚无同类产品上市，属潜 在 FIC（First in class）项目。Ib 期和 II 期临床试验研究结果显示，GST-HG141 片具有显著药效和良好的安全性，并且起效快，在核苷类药物治疗基础上对 HBV DNA 具有进一步显著抑制和转阴效果，且明显降低和转阴 HBV pgRNA，间接体现 了对 HBV cccDNA 的潜在有效抑制和耗竭作用，因此有潜力成为新的乙肝治疗基 石药物，重构乙肝防线。2024 年 11 月，GST-HG141 的 II 期临床研究成果被全球 肝病研究领域专业学术机构美国肝病研究协会（AASLD）作为最新突破摘要 1 证券代码：300436 证券简称：广生堂 公告编号：2026004 福建广生堂药业股份有限公司 关于乙肝治疗一类创新药奈瑞可韦 GST-HG141 完成 III 期 临床试验受试者入组的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（以下简称"公司"）创新药 ...

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovative development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63%, with a total market value of 4.285 billion [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion [2] - Shutaishen rose by 3.94%, with a total market value of 1.3 billion [2] - Beilu Pharmaceutical increased by 3.49%, with a total market value of 584.3 million [2] - Tigermed rose by 3.37%, with a total market value of 56.3 billion [2]

Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovation and development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63% with a total market value of 42.85 billion and a year-to-date increase of 18.07% [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion and a year-to-date increase of 29.53% [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion and a year-to-date increase of 4.53% [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion and a year-to-date decrease of 2.89% [2] - Shutaishen and Beilu Pharmaceutical both saw increases of over 3%, with market values of 13 billion and 5.843 billion respectively [2]

近日，广生堂发布公告称，预计2025年度归母净利润亏损约为1.7亿元至2.4亿元，扣除非经常性损益后的净利润预计 亏损约为1.77亿元至2.48亿元。 公告中提到，业绩亏损的主要原因包括持续的研发投入以及前期固定资产投资较大，导致研发费用和管理费用保持在 较高水平。此外，预计非经常性损益对公司归母净利润的影响约为750万元，同比减少约3573万元，主要因政府补助 大幅减少。 （广生堂公告） ...

Market Performance - The chemical pharmaceutical sector increased by 1.41% on February 3, with Yiming Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Top Gainers in Chemical Pharmaceutical Sector - Yiming Pharmaceutical (002826) closed at 20.98, up 9.27% with a trading volume of 269,200 shares and a transaction value of 559 million [1] - Yuandong Biological (688513) closed at 68.90, up 8.85% with a trading volume of 64,600 shares [1] - Nami Technology (688690) closed at 29.00, up 7.01% with a trading volume of 93,900 shares and a transaction value of 265 million [1] - Lianhuan Pharmaceutical (600513) closed at 20.15, up 5.94% with a trading volume of 162,200 shares and a transaction value of 323 million [1] Top Losers in Chemical Pharmaceutical Sector - Shuangbi Pharmaceutical (002038) closed at 6.41, down 7.10% with a trading volume of 801,300 shares and a transaction value of 511 million [2] - Haizhi Pharmaceutical (002653) closed at 47.50, down 5.47% with a trading volume of 90,200 shares and a transaction value of 430 million [2] - Nuo Cheng Jianhua (688428) closed at 21.13, down 3.78% with a trading volume of 163,500 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 42.01 million from institutional investors, while retail investors saw a net inflow of 651 million [2] - The main capital inflow was observed in Yiming Pharmaceutical with 58.98 million, while it faced a net outflow of 58.77 million from retail investors [3] - Other notable inflows included Guangsheng Tang (300436) with 14.8 million from main capital, while it faced a net outflow of 95.56 million from retail investors [3]

证券之星消息，2月2日化学制药板块较上一交易日下跌2.74%，常山药业领跌。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。化学制药板块个股涨跌见下表： 从资金流向上来看，当日化学制药板块主力资金净流出17.84亿元，游资资金净流入4.59亿元，散户资金 净流入13.25亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002099 海翔药业 | | 8825.41万 | 12.82% | -5616.28万 | -8.16% | -3209.13万 | -4.66% | | 300436 | 广生堂 | 7859.33万 | 6.93% | -2678.33万 | -2.36% | -5181.00万 | -4.57% | | 600513 联环药业 | | 3551.00万 | 13.02% | -876.01万 | -3. ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本次业绩预告相关财务数据是公司财务部门初步测算的结果，未经会计师事务所审计。公司已就本报告 期业绩预告有关事项与会计师事务所进行预沟通，双方在本次业绩预告方面不存在重大分歧。 证券代码：300436 证券简称：广生堂 公告编号：2026003 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为负值 二、与会计师事务所沟通情况 2、公司基于谨慎性原则，对报告期末合并报表范围内无形资产、存货、固定资产等资产进行减值测 试，对发生减值的资产计提减值准备。 3、报告期内，预计非经常性损益对公司归属于上市公司股东的净利润的影响约750万元，同比减少约 3,573万元，主要是政府补助大幅减少。 上述计提资产减值准备等财务数据情况未经会计师事务所审计，计提资产减值准备的相关评估工作正在 进行中，最终数据以会计师事务所审计结果为准。 四、其他相关说明 2025年年度具体财务数据将在公司2025年年度报告中详细披露， ...